Monte Rosa Therapeutics I...

NASDAQ: GLUE · Real-Time Price · USD
4.45
0.10 (2.30%)
At close: Aug 15, 2025, 10:05 AM

Monte Rosa Therapeutics Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Income
-72.7M -135.35M -108.5M -73.96M
Depreciation & Amortization
8.12M 6.22M 3.75M 2.13M
Stock-Based Compensation
18.13M 16.67M 11.66M 5.2M
Other Working Capital
84.81M 64.81M -1.39M 6.99M
Other Non-Cash Items
-2.95M -3.81M 2.76M 960K
Deferred Income Tax
n/a n/a n/a 17K
Change in Working Capital
91.4M 72.47M -2.13M 6.29M
Operating Cash Flow
42M -43.8M -92.47M -59.36M
Capital Expenditures
-3.99M -19.04M -12.91M -9.73M
Cash Acquisitions
n/a 62K 109K 79K
Purchase of Investments
-230.36M -103.15M -384.42M n/a
Sales Maturities Of Investments
189.9M 210.93M 178M n/a
Other Investing Acitivies
n/a n/a n/a n/a
Investing Cash Flow
-44.45M 88.8M -219.22M -9.65M
Debt Repayment
n/a n/a n/a n/a
Common Stock Repurchased
-641K n/a n/a n/a
Dividend Paid
n/a n/a n/a n/a
Other Financial Acitivies
98.59M n/a 411K -3.19M
Financial Cash Flow
98.89M 27.49M 20.47M 377.56M
Net Cash Flow
96.44M 72.49M -291.22M 308.55M
Free Cash Flow
38.01M -62.84M -105.38M -69.09M